Royalty Pharma PLC (NAS:RPRX)
$ 28.09 0.12 (0.43%) Market Cap: 12.67 Bil Enterprise Value: 17.27 Bil PE Ratio: 15.87 PB Ratio: 1.95 GF Score: 79/100

Royalty Pharma PLC at TD Cowen Health Care Conference Transcript

Mar 05, 2024 / 03:30PM GMT
Release Date Price: $29.43 (-1.54%)
Stephen Scala
TD Cowen, Research Division - MD & Senior Research Analyst

Good morning, everyone. Welcome to the Royalty Pharma session. Thanks for joining us. We're very pleased to welcome Pablo Legorreta, who's the Founder and CEO of Royalty Pharma as well as Marshall Urist, who is the Head of Research and Investments. Thanks for joining us, gentlemen.

Pablo Legorreta
Royalty Pharma plc - Founder, Chairman of the Board & CEO

Thank you for inviting us.

Marshall Urist
Royalty Pharma plc - Executive VP and Head of Research & Investments

Great to be here.

Questions & Answers

Stephen Scala
TD Cowen, Research Division - MD & Senior Research Analyst

So I'll start with something of a bigger picture question. Regarding your 2030 target of $4.7 billion plus in portfolio receipts, unlike a traditional pharma company with a published pipeline that can be evaluated, should we understand that most of the gap between Royalty Pharma's current revenue and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot